Novartis receives European Commission approval for Itvisma for spinal muscular atrophy
2nd July 2026 Uncategorised 0
EC backs first gene replacement therapy for broad sma population

More: Novartis receives European Commission approval for Itvisma for spinal muscular atrophy
Source: News
